BRENTUXIMAB VEDOTIN VS PHYSICIAN'S CHOICE IN CTCL PATIENTS FROM THE PHASE 3 ALCANZA STUDY: ANALYSIS OF OUTCOMES BY CD30 EXPRESSION. (June 2017)

• Record Type: Journal Article
• Authors: Kim, Y.H.; Prince, H.M.; Whittaker, S.; Horwitz, S.M.; Duvic, M.; Scarisbrick, J.; Quaglino, P.; Zinzani, P.L.; Wolter, P.; Bechter, O.; Wang, Y.; Palanca‐Wessels, M.C.; Wood, K.W.; Li, M.; Liu, Y.; Lin, H.; Little, M.; Danaee, H.; Trepicchio, W.; Dummer, R.
• Is Part Of: Hematological oncology. Volume 35(2017)Supplement 2
• Page Start: 77
• Page End: 78
• Publication Date: 2017-06
• Subjects: Hematological oncology -- Periodicals; Hematology; Medical Oncology; 616.99418005
• DOI: 10.1002/hon.2437_65
• Languages: English
• ISSNs: 0278-0232